ArticleCureus2025
The Impact of Hyperuricemia on the Progression of Atherosclerotic Cardiovascular Disease.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Calcineurin Inhibitors and Uric Acid Control in Solid Organ Transplantation: A Systematic Review.Medical sciences (Basel, Switzerland) · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperuricemia refers to elevated levels of serum uric acid (SUA) beyond the normal physiological range in men and women. It is caused by increased endogenous synthesis, decreased renal clearance, or a combination. While hyperuricemia has long been associated with gout, new evidence suggests that it is a significant risk factor in the pathophysiology of a variety of cardiovascular and metabolic disorders, including hypertension, metabolic syndrome, coronary artery disease, heart failure, type 2 diabetes mellitus, and chronic kidney disease. The increasing global frequency of hyperuricemia has sparked scientific and clinical interest in the possible mechanistic relationship between elevated SUA levels and cardiovascular morbidity. Hyperuricemia's pathological mechanisms, including oxidative stress, endothelial dysfunction, and systemic inflammation, may lead to vascular remodeling, atherosclerotic plaque progression, and increased cardiovascular mortality. This case report emphasizes the need for increased clinical awareness of the cardiovascular dangers associated with asymptomatic hyperuricemia. Its purpose is to investigate the potential link between elevated SUA and the severity of coronary artery involvement, emphasizing the importance of early detection and treatment of hyperuricemia as a modifiable cardiovascular risk factor.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.